Literature DB >> 32445862

Can we safely reduce the radiation dose to the heart while compromising the dose to the lungs in oesophageal cancer patients?

Jannet C Beukema1, Yoshifumi Kawaguchi2, Nanna M Sijtsema3, Tian-Tian Zhai3, Johannes A Langendijk3, Lisanne V van Dijk3, Peter van Luijk3, Teruki Teshima2, Christina T Muijs3.   

Abstract

PURPOSE: The aim of this study was to evaluate which clinical and treatment-related factors are associated with heart and lung toxicity in oesophageal cancer patients treated with chemoradiation (CRT). The secondary objective was to analyse whether these toxicities are associated with overall survival (OS).
MATERIALS AND METHODS: The study population consisted of a retrospective cohort of 216 oesophageal cancer patients treated with curative CRT. Clinical and treatment related factors were analysed for OS and new pulmonary and cardiac events by multivariable regression analyses. The effect of these toxicities on OS was assessed by Kaplan Meyer analyses.
RESULTS: Multivariable analysis revealed that pulmonary toxicity was best predicted by the mean lung dose. Cardiac complications were diverse; the most frequently occurring complication was pericardial effusion. Several cardiac dose parameters correlated with this endpoint. Patients developing radiation pneumonitis had significantly worse OS than patients without radiation pneumonitis, while no difference was observed in OS between patients with and without pericardial effusion. OS was best predicted by the V45 of the lung and tumour stage. None of the cardiac dose parameters predicted OS in multivariable analyses.
CONCLUSION: Cardiac dose volume parameters predicted the risk of pericardial effusion and pulmonary dose volume parameters predicted the risk of radiation pneumonitis. However, in this patient cohort, pulmonary DVH parameters (V45) were more important for OS than cardiac DVH parameters. These results suggest that reducing the cardiac dose at the expense of the dose to the lungs might not always be a good strategy in oesophageal cancer patients.
Copyright © 2020 The Author(s). Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Chemoradiation; Heart toxicity; Lung toxicity; Oesophageal cancer; Overall survival

Mesh:

Year:  2020        PMID: 32445862     DOI: 10.1016/j.radonc.2020.05.033

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  2 in total

1.  Mean heart dose-based normal tissue complication probability model for pericardial effusion: a study in oesophageal cancer patients.

Authors:  Junichi Fukada; Kyohei Fukata; Naoyoshi Koike; Ryuichi Kota; Naoyuki Shigematsu
Journal:  Sci Rep       Date:  2021-09-13       Impact factor: 4.379

2.  Impact of Blood Parameters and Normal Tissue Dose on Treatment Outcome in Esophageal Cancer Patients Undergoing Neoadjuvant Radiochemotherapy.

Authors:  Rebecca Bütof; Laura Häberlein; Christina Jentsch; Jörg Kotzerke; Fabian Lohaus; Sebastian Makocki; Chiara Valentini; Jürgen Weitz; Steffen Löck; Esther G C Troost
Journal:  Cancers (Basel)       Date:  2022-07-19       Impact factor: 6.575

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.